<DOC>
	<DOCNO>NCT02838121</DOCNO>
	<brief_summary>Periprosthetic bone loss cause stress-shielding effect , phenomenon bone atrophy mechanical unload THR implantation , compromise longevity implant . The prospective randomized study aim investigate periprosthetic bone loss primary total hip replacement .</brief_summary>
	<brief_title>Prevention Periprosthetic Bone Loss After Total Hip Replacement Annual Bisphosphonate Therapy</brief_title>
	<detailed_description>This study prospective , randomize , open-label clinical trial . The study perform patient obtain informed consent . Group assignment draw seal envelops base random table . ( 1 ) Group 1 : Experimental group 30 case , AclastaÂ® ( Zoledronic acid 5mg/100ml ) give intravenously 4th postoperative day one year total hip replacement , ( 2 ) Group 2 : Control group , 30 case , bisphosphonate give patient . Only unilateral coxarthrosis recruit study . Patients analyze ( 1 ) DXA study ( 2 ) Clinical assessment ( Harris hip score SF-12 ) ( 3 ) X-ray ( 4 ) serum marker bone turnover . Patients schedule specified examination preoperatively , postoperatively 6 week , 3 month , 6 month , 12 month , 24 month .</detailed_description>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Male female , 35 85 year age 2 . Indicated Total hip replacement various hip diseases 3 . Has preoperative DXA study within 3 month total hip replacement procedure willing receive preoperative DXA study baseline comparison 4 . Signed write informed consent 5 . Standard transgluteal approach total hip replacement use Zimmer Triology Cup Versys Fiber Metal Taper Stem metal highly crosslinked polyethylene bearing surface 1 . Any prior use intravenous bisphosphonate within last 2 year 2 . Uncontrolled seizure disorder associate fall 3 . A history invasive malignancy organ system , treat untreated , within past five year ; exclude , basal cell squamous cell carcinoma skin , colonic polyp noninvasive malignancy remove 4 . Carcinoma situ uterine cervix 5 . History osteogenesis imperfecta , multiple myeloma , Paget 's disease 6 . Active primary hyperparathyroidism 7 . History iritis uveitis 8 . Selfreported history diabetic nephropathy retinopathy 9 . AST ALT twice upper limit normal 10 . Alkaline phosphatase twice upper limit normal 11 . Serum calcium 2.75 mmol/L ( 11.0 mg/dL ) 12 . Baseline renal insufficiency ( calculated creatinine clearance 35 ml/min ) 13 . History hypersensitivity bisphosphonates 14 . Use investigational drug ( ) and/or device within 30 day prior randomization 15 . Any medical psychiatric condition , Investigator 's opinion , would preclude participant adhere Protocol complete trial per protocol 16 . Use hip protector 17 . With implant prosthesis contralateral hip joint</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>bisphosphonate</keyword>
	<keyword>Total hip replacement</keyword>
	<keyword>functional outcome</keyword>
	<keyword>bone mineral density</keyword>
</DOC>